The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Living a healthy life means knowing the symptoms of chlamydia and taking the necessary precautions under a doctor's guidance.

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...

Visby Medical’s at-home diagnostic, which can be purchased without a prescription, tests for chlamydia, gonorrhea and trichomoniasis.

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

US FDA grants marketing authorization of first home test for Chlamydia, gonorrhoea and trichomoniasis: Silver Spring, Maryland Monday, March 31, 2025, 10:00 Hrs [IST] The US Food ...

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Caused by the bacterium Chlamydia trachomatis, chlamydia is a common bacterial infection of the reproductive tract that can lead to infertility and pregnancy complications. The vaccine candidate ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.